New eczema therapy findings from German Cancer Research Center described
2007 AUG 21 -- Research findings, "Anti-CD44-mediated blockade of leukocyte migration in skin-associated immune diseases," are discussed in a new report. "CD44 plays an important role in leukocyte extravasation, which is fortified in autoimmune diseases and delayed-type hypersensitivity (DTH) reactions. There is additional evidence that distinct CD44 isoforms interfere with the extravasation of selective leukocyte subsets," researchers in Heidelberg, Germany report. "We wanted to explore this question in alopecia areata (AA), a hair-follicle centric autoimmune disease, and in a chronic eczema. The question became of interest because AA is treated efficiently by topical application of a contact sensitizer, such that a mild DTH reaction is maintained persistently. Aiming to support the therapeutic efficacy of a chronic eczema in AA by anti-CD44 treatment, it became essential to control whether a blockade of migration, preferentially of AA effector cells, could be achieved by CD44 isoform-specific antibodies. Anti-panCD44 and anti-CD44 variant 10 isoform (CD44v10) inhibited in vitro migration of leukocytes from untreated and allergen-treated, control and AA mice. In vivo, both antibodies interfered with T cell and monocyte extravasation into the skin; only anti-panCD44 prevented T cell homing into lymph nodes. Contributing factors are disease-dependent alterations in chemokine/chemokine receptor expression and a blockade of CD44 on endothelial cells and leukocytes. It is important that CD44 can associate with several integrins and ICAM-1. Associations depend on CD44 activation and vary with CD44 isoforms and leukocyte subpopulations. CD44 standard isoform preferentially associates with CD49d in T cells and CD44v10 with CD11b in monocytes. Accordingly, anti-panCD44 and anti-CD49d inhibit T cell, anti-CD11b, and anti-CD44v10 macrophage migration most efficiently," wrote M. Zöller and colleagues, German Cancer Research Center. The researchers concluded: "Thus, allergen treatment of AA likely can be supported by targeting AA T cells selectively via a panCD44-CD49d-bispecific antibody." Zöller and colleagues published their study in the Journal of Leukocyte Biology (Anti-CD44-mediated blockade of leukocyte migration in skin-associated immune diseases. Journal of Leukocyte Biology, 2007;82(1):57-71). For additional information, contact M. Zöller, German Cancer Research Center, Dept. of Tumor Progression and Tumor Defense, Heidelberg, Germany. Publisher contact information for the Journal of Leukocyte Biology is: Federation American Society Experimental Biology, 9650 Rockville Pike, Bethesda, MD 20814-3998, USA. Keywords: Germany, Heidelberg, Eczema Therapy, Autoimmune Disease, Autoimmune Disorder, Cancer Research, Dermatology, Eczema, Immunology, Leukocyte Biology, Rheumatology. This article was prepared by Life Science Weekly editors from staff and other reports. Copyright 2007, Life Science Weekly via NewsRx.com.
|
